Increased focus on drug discovery, accelerated delivery of new treatments for patients, introduction of novel and highly efficient therapies, a variety of new drugs entering the market, huge R&D activities & investments in multiple sclerosis (MS) therapeutics clinical development are key factors contributing to high CAGR of Multiple Sclerosis Therapeutics during forecast period.

According to the current analysis of Reports and Data, the global Multiple Sclerosis Therapeutics market was valued at USD 21.92 Billion in 2019 and is expected to reach USD 26.69 Billion by year 2027, at a CAGR of 2.5 %. Multiple Sclerosis is a disabling condition of the central nervous system that impairs the flow of information within the brain and between the body and the brain. The intensity of Multiple Sclerosis ranges from numbness and tingling to blindness and paralysis. Every person with Multiple Sclerosis has a different symptom, which makes the diagnosis difficult. Increasing research related to the signs and treatments related to Multiple Sclerosis is expected to drive the market growth. Another challenge faced by the Multiple Sclerosis therapeutics market is the lack of awareness among the people associated with the Multiple Sclerosis condition. The demand for Multiple Sclerosis is expected to increase owing to the new drug developments for treating Multiple Sclerosis. For instance, according to an article published on July 31, 2019, by the National MS Society, Dalfampridine tablets are expected to improve the information processing speed in people who have Multiple Sclerosis. Increasing awareness among the people in developing nations, coupled with an increase in the developments in the healthcare sector, is further expected to drive the market for Multiple Sclerosis therapeutics. Additionally, the increasing research and study associated with Multiple Sclerosis are expected to increase the market for Multiple Sclerosis therapeutics in the coming years. University College London researchers explained how the early MRI signs might indicate the future disease course of Multiple Sclerosis. 

Key companies profiled in the report include

Biogen Idec, Teva Pharmaceuticals, Bayer Healthcare, Pfizer, Sanofi-Aventis, Merck, and Novartis, AbbVie Inc., Acorda Therapeutics Inc.

Get a sample of the report @

The report is an investigative study that determines market growth and market scope on the basis of market trends, consumer behavior shifts, consumption and production patterns, product portfolio offered by the market, growth rate, drivers and constraints, financial positions, and existing challenges and limitations of the Multiple Sclerosis Therapeutics market.

The report discusses in detail the global production capacity, demand and supply ratio, market dynamics, and comprehensive analysis of the competitive landscape. It provides an industry-wide analysis of the market share of each players along with their business portfolio, production and manufacturing capacity, product portfolio, business expansion plans, financial standing, and strategic alliances such as mergers and acquisitions, joint ventures, and collaborations, among others.

Order this Report @

The regional bifurcation of the market analyzes key market segments such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The report discusses in detail the market growth, market size, revenue growth, market share, production and consumption, demand and supply, current and emerging trends, and technological developments in each region.

The key geographical regions analyzed in the market report are:

  • North America (U.S.A., Canada)
  • Europe (U.K., Italy, Germany, France, Rest of EU)
  • AsiaPacific (India, Japan, China, South Korea, Australia, Rest of APAC)
  • Latin America (Chile, Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Multiple Sclerosis Therapeutics Market Segmentation based on Types:

Product Type (Revenue, USD Million; 2017–2027)

  • Immunomodulators
    • Ponesimod
    • Glatopa
    • Copaxone
    • Avonex
    • Fingolimod
    • Teriflunomide
    • Others
  • Immunosuppressant
    • Cladribine
    • Others
  • Corticosteroids
    • Prednisone
    • Methylprednisolone
  • Beta interferons
    • Betaseron
    • Others
  • Others

Mode of Administration Type (Revenue, USD Million; 2017–2027)

  • Injectable
  • Intravenous
  • Oral

Distribution Channel (Revenue, USD Million; 2017–2027)

  • Healthcare Providers
  • Online Pharmacies
  • Medical Clinics
  • Others

Further key findings from the report suggest

  • Multiple Sclerosis Therapeutics market is growing at a CAGR of 8% in North America followed by Asia Pacific and Europe, with 2.7 % and 2.3% CAGR, respectively. Launch of novel therapeutics is the key factor to accelerate the market growth during forecast period across all regions.
  • As of 2019, Immuno-modulators is the dominating Multiple Sclerosis Therapeutics which holds 71.9% of the global market. North American regional market is the chief revenue generating source for this product segment, followed by Asia-Pacific and Europe regions.
  • Multiple Sclerosis has no permanent cure, however, many treatments and medications are available to keep manage the symptoms. Drugs are available to slow down the symptoms and intensity of multiple sclerosis.
  • One of the major challenges faced by healthcare specialist is that, since Multiple Sclerosis is the condition that affects the brain and the spinal cord, Multiple Sclerosis intensity and symptoms for every person is different. This makes the detection and the treatment of the condition even more difficult.
  • A new study funded by the National MS Society has confirmed that nearly one million people are living with MS in the United States, more than twice the original estimate from a previous study.
  • Several risk factors, including genes, exposure to infections, and environmental factors, have been identified as growing a person’s vulnerability to developing multiple sclerosis. In addition, there is a growing body of evidence that adolescent obesity can increase the possibility of developing MS.
  • May 30th was officially market as the World MS Day. World MS Day Multiple Sclerosis movement’s annual campaign started to increase the awareness among the people and support and connect the people suffering from multiple sclerosis all around the world.
  • A recent study published in the journal Multiple Sclerosis and Related Disorders states that, the effect of not taking the medication of Multiple Sclerosis not only affects the management of the MS condition, but also affects the general health of the patient.
  • Lifestyle factors are not risk factors for developing MS, for example, diet, exercise, tobacco use, unlike conditions in which these risk factors are very important, such as stroke, heart disease, or diabetes.

Request a customization on the report @

Thank you for reading our report. For further inquiry or query about customization, kindly get in touch with us to know more. Our team will clear your doubts and ensure the report is customized to meet your requirements.

Browse More Reports:

Insulin Pumps Market @

Cell Viability Assays Market @

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W

Head of Business Development

Reports and Data | Web:

Direct Line: +1-212-710-1370